These stable cell lines showed increased expression levels of CXCR7 as well as NE markers ENO2 and SYP, mimicking clinical situations where patients with advanced PCa develop resistance to ARPi treatment and start to gain NE features (Supplemental Figure 2A). Here, ACKR3 is linked to posterior cortical atrophy.